The Downside Of REMS: An Over-Taxed Health Care System – FDA’s Jenkins
Executive Summary
The increasing number of Risk Evaluation & Mitigation Strategies for drug and biotechnology products could cripple the current health care system - and force an overhaul of the way REMS are administered
You may also be interested in...
Alexion's Soliris Adds Prescriber Certification In Move From RiskMAP To REMS
The REMS for the hemolysis drug seems to be more onerous than the previous RiskMAP, although the company says there are no new safety problems behind the change.
FDA Kicks Off Opioid Class REMS Discussion; Asks For Industry Collaboration
FDA laid out general guidelines for a class-wide Risk Evaluation and Mitigation Strategy for opioid pain products during a closed-door meeting March 3, and urged manufacturers to work collaboratively to help develop a proposal as soon as possible
FDA Kicks Off Opioid Class REMS Discussion; Asks For Industry Collaboration
FDA laid out general guidelines for a class-wide Risk Evaluation and Mitigation Strategy for opioid pain products during a closed-door meeting March 3, and urged manufacturers to work collaboratively to help develop a proposal as soon as possible